Trial Profile
Phase I Study of Ublituximab and Umbralisib in Combination With Targeted Immunotherapy in Patients With Relapsed-refractory Chronic Lymphocytic Leukemia (CLL) or Richter's Transformation (RT) of CLL
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 13 Jan 2022
Price :
$35
*
At a glance
- Drugs Cosibelimab (Primary) ; Ublituximab (Primary) ; Umbralisib (Primary) ; Pembrolizumab
- Indications Chronic lymphocytic leukaemia; Richter's syndrome
- Focus Adverse reactions
- Sponsors TG Therapeutics Inc
- 21 Dec 2021 Status changed from active, no longer recruiting to completed.
- 20 Sep 2021 Results presented in the TG Therapeutics Media Release.
- 30 Aug 2021 According to a TG Therapeutics Inc media release, data from this trial will be presented at the upcoming XIX International Workshop on Chronic Lymphocytic Leukemia (iwCLL), being held virtually in September 2021.